| Bioactivity | ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin, which has the ability to continuously improve glycemic control. Meanwhile, ZP3022 can effectively increase the mass of β-cells, promote β-cell proliferation, and enhance the average islet mass. ZP3022 can be used in research for anti-diabetic treatments[1]. |
| Sequence | His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-(8Ado)-(8Ado)-Tyr-Gly-Trp-Leu-Asp-Phe-NH2 8Ado: 8-amino-3,6-dioxaoctanoic acid |
| Shortening | HGEGTFTSDLSKQMEEEAVRLFIEWLKN-(8Ado)-(8Ado)-YGWLDF-NH2 8Ado: 8-amino-3,6-dioxaoctanoic acid |
| Formula | C199H294N48O61S |
| Molar Mass | 4366.81 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Dalbøge LS, et al. The novel GLP-1-gastrin dual agonist ZP3022 improves glucose homeostasis and increases β-cell mass without affecting islet number in db/db mice. J Pharmacol Exp Ther. 2014;350(2):353-360. |